Amarin (AMRN) Projected to Release Earnings on Wednesday

Amarin (NASDAQ:AMRN) will likely be releasing its Q2 2026 results before the market opens on Wednesday, July 29th. Analysts expect the company to announce earnings of ($0.01) per share and revenue of $44.55 million for the quarter. Investors are encouraged to explore the company’s upcoming Q2 2026 earning report page for the latest details on the call scheduled for Wednesday, July 29, 2026 at 8:00 AM ET.

Amarin Stock Performance

Shares of AMRN stock opened at $13.55 on Monday. The company has a market cap of $284.14 million, a price-to-earnings ratio of -20.85 and a beta of 0.80. The stock has a 50 day simple moving average of $14.90 and a 200-day simple moving average of $14.88. Amarin has a 12-month low of $12.96 and a 12-month high of $20.90.

Institutional Investors Weigh In On Amarin

Hedge funds and other institutional investors have recently modified their holdings of the stock. Banque Cantonale Vaudoise purchased a new stake in shares of Amarin during the 3rd quarter worth approximately $32,000. Headlands Technologies LLC acquired a new position in Amarin during the second quarter worth $44,000. Northwestern Mutual Wealth Management Co. raised its holdings in Amarin by 1,816.7% during the third quarter. Northwestern Mutual Wealth Management Co. now owns 5,750 shares of the biopharmaceutical company’s stock worth $94,000 after purchasing an additional 5,450 shares during the last quarter. New York State Common Retirement Fund boosted its position in Amarin by 56.8% during the fourth quarter. New York State Common Retirement Fund now owns 7,605 shares of the biopharmaceutical company’s stock worth $106,000 after purchasing an additional 2,756 shares in the last quarter. Finally, Wells Fargo & Company MN boosted its position in Amarin by 34.8% during the fourth quarter. Wells Fargo & Company MN now owns 9,254 shares of the biopharmaceutical company’s stock worth $129,000 after purchasing an additional 2,390 shares in the last quarter. 22.25% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of brokerages recently weighed in on AMRN. Zacks Research raised Amarin from a “hold” rating to a “strong-buy” rating in a report on Tuesday, June 16th. Wall Street Zen cut Amarin from a “buy” rating to a “hold” rating in a research report on Saturday. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Amarin in a report on Friday, July 17th. One analyst has rated the stock with a Strong Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, Amarin presently has an average rating of “Moderate Buy”.

Amarin Company Profile

Amarin Corporation plc is a biopharmaceutical company focused on the commercialization and development of therapeutics for cardiovascular health. Founded in 1993 and headquartered in Dublin, Ireland, the company is publicly traded on the NASDAQ under the ticker AMRN. Amarin’s primary mission is to improve cardiovascular outcomes through innovative lipid science and evidence-based therapies.

The company’s flagship product is Vascepa® (icosapent ethyl), a high-purity prescription omega-3 fatty acid approved for the treatment of severe hypertriglyceridemia and as an adjunct to statin therapy to reduce the risk of cardiovascular events.